Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates

This podcast features Sam Fazeli, a Senior Pharmaceutical Analyst, interviewing Dr. Susan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, about data presented at the European Society for Medical Oncology (ESMO) conference. They discuss AstraZeneca's data in breast cancer, focusing on early intervention with antibody-drug conjugates (ADCs) like Enhertu in HER2 positive patients, and the Destiny Breast trials (DB11 and DB05). The conversation covers pathologic complete response rates, safety profiles, and the potential for improved overall survival. They also discuss oral SERDs, particularly camizestrin, for HR positive breast cancer, and the TROP2 ADC, Datroway, for triple negative breast cancer. Finally, they touch on bladder cancer, comparing the Potomac trial results with other studies and discussing the potential of various treatment combinations.